2
Learning Objectives At the conclusion of this presentation participants should understand the following: Use of pharmacogenetics in understanding patient susceptibility to 5-FU/capecitabine toxicity Toxicity risk associated with variations in DPYD and TYMS –DPYD = DPD deficiency –TYMS= TS deficiency Use of genetic test results in medical management